Clinical Trial Update: Ph 2 Elacestrant in ER Positive Uterine Sarcomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of elacestrant for estrogen receptor-positive uterine sarcomas is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Stromal Sarcoma
• Perivascular Epithelioid Cell Tumor
• Uterine Adenosarcoma
• Uterine Leiomyosarcoma
• Uterine Sarcoma

Drugs mentioned

• Elacestrant (elacestrant)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Uterine Sarcoma, Uterine Leiomyosarcoma | Phase 2 | Status: RECRUITING